Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses the longstanding treatment options used in addition to chemotherapy, including antiadrogens and CYP inhibitors.…
Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses Androgen Deprivation Therapy. Androgen Deprivation Therapy is the gold standard for men with metastatic…
Recent Videos in Best Practice Series: Prostate Cancer Page 2
NEW YORK (Reuters Health) – There appear to be several problems with the current clinical staging criteria for localized prostate cancer, according to a study published online today…
NEW YORK (Reuters Health) – Despite declining use, perineal radical prostatectomy (PRP) yields outcomes that are equal to, or better than, those of retropubic radical prostatectomy (RRP) and…
NEW YORK (Reuters Health) – Men whose baseline PSA is less than 2.0 ng/mL are unlikely to benefit from further screening for prostate cancer, according to findings reported…
NEW YORK (Reuters Health) – Among men who’ve had a negative prostate biopsy, the velocity of increasing prostate specific antigen (PSA) levels is not helpful in deciding whether…
NEW YORK (Reuters Health) – Patients with localized prostate cancer can be treated successfully with high-intensity focused ultrasound (HIFU), with results comparable to those expected with external-beam radiation…
NEW YORK (Reuters Health) – For locally advanced and metastatic prostate cancer, the best timing and duration of androgen-deprivation therapy (ADT) is unclear. Now, a systematic review suggests…
NEW YORK (Reuters Health) – Mounting evidence suggests that preoperative prostate specific antigen (PSA) kinetics are a poor marker of disease progression. During active surveillance for low-risk, low-volume…
NEW YORK (Reuters Health) – Prostate specific antigen (PSA) doubling time as measured before radical prostatectomy does not predict biochemical progression after surgery, according to a report in…
NEW YORK (Reuters Health) – Treatment with dutasteride reduces incident prostate cancers in men with high prostate specific antigen (PSA) levels, according to a report in The New…
NEW YORK (Reuters Health) – Androgen suppression therapy – and its attendant side effects — may not be necessary for patients with intermediate-risk prostate cancer treated with combination…
